Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C20H28N2O2 and a molecular weight of approximately 328.45 g/mol. It is classified as an experimental drug and has not been approved for any medical use in the United States or elsewhere. There are no known clinical trials, patents, or indicated conditions associated with this molecule. Its mechanism of action, pharmacological activity, therapeutic indication, developer(s), and manufacturer(s) have not been described in publicly available sources[1][3][5]. The structure features a pyridinone core substituted with ethyl, methyl, methoxyethylmethylamino, and methylbenzyl groups.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-ethyl-3-[(2-methoxyethyl)methylamino]-6-methyl-4-(3-methylbenzyl)pyridin-2(1H)-one.